IFP Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

IFP Advisors’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	200	–	–	﹤0.01%	5326
2026 Q1	$0	Hold	200	–	–	﹤0.01%	5209
2025 Q4	$0	Hold	200	–	–	﹤0.01%	5080
2025 Q3	$0	Hold	200	–	–	﹤0.01%	4986
2025 Q2	$0	Buy	+200	New	–	﹤0.01%	5080
2023 Q1	–	Sell	-18	Closed	-$8K	–	4703
2022 Q4	$8K	Hold	18	–	–	﹤0.01%	3575
2022 Q3	$8K	Hold	18	–	–	﹤0.01%	3827
2022 Q2	$8K	Hold	18	–	–	﹤0.01%	3573
2022 Q1	$8K	Buy	+18	New	+$8K	﹤0.01%	3572
2019 Q1	–	Sell	-1,000	Closed	-$7K	–	4017
2018 Q4	$7K	Hold	1,000	–	–	﹤0.01%	2734
2018 Q3	$8K	Hold	1,000	–	–	﹤0.01%	3031
2018 Q2	$7K	Sell	1,000 -1,000	-50%	-$7.87K	﹤0.01%	3136
2018 Q1	$16K	Hold	2,000	–	–	﹤0.01%	2549
2017 Q4	$16K	Hold	2,000	–	–	﹤0.01%	2585
2017 Q3	$14K	Hold	2,000	–	–	﹤0.01%	2861
2017 Q2	$14K	Buy	2,000 +1,000	+100%	+$5.48K	﹤0.01%	2835
2017 Q1	$6K	Hold	1,000	–	–	﹤0.01%	3256
2016 Q4	$6K	Hold	1,000	–	–	﹤0.01%	3257
2016 Q3	$6K	Hold	1,000	–	–	﹤0.01%	3196
2016 Q2	$6K	Buy	+1,000	New	+$6.13K	﹤0.01%	3113
2016 Q1	–	Sell	-1,000	Closed	-$6K	–	4559
2015 Q4	$6K	Buy	+1,000	New	+$5.38K	﹤0.01%	2930

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

IFP Advisors's SVA Position: Q2 2026 in Review

IFP Advisors held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 200 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5326.

IFP Advisors first reported a position in SVA in Q4 2015 and has held it in 21 quarters since. The position peaked at $16K in Q1 2018. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

IFP Advisors held 200 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
IFP Advisors left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5326 holding.
IFP Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2015 and has held it in 21 quarters since.
IFP Advisors's Sinovac Biotech, Ltd position peaked at $16K in Q1 2018.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.